

# SPRING 2009 PLENARY SESSION

## Southwest Oncology Group Showcase 2009

Friday, April 24, 2009, 12:15 p.m. - 2:45 p.m.

Grand Ballroom

### Chair's Commentary and Presentation

**Laurence H. Baker, D.O.**, Group Chair

### **Oxaliplatin (OXP) Plus Protracted Infusion 5-Fluorouracil (PIFU) and External Beam Radiation (EBRT) Prior to Surgery (S) for Potentially Curable Esophageal Adenocarcinoma (EA): A Southwest Oncology Group (SWOG) Phase II Trial with Molecular Correlates (S0356)**

**Presenter:** **Lawrence P. Leichman, M.D.**, Director, GI Cancer Research Aptium Oncology; and Director, Aptium Oncology GI Cancer Consortium (AGICC) Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, CA

**Discussant:** **Peter Enzinger, M.D.**, Clinical Director, GI Cancer Center, Dana Farber Cancer Institute; and Assistant Professor of Medicine, Harvard Medical School, Boston, MA

### **Chemoradiation of Resected Gastric Cancer: A 10 Year Follow-up of the Phase III Trial INT0116 (SWOG 9008)**

**Presenter:** **Jack MacDonald, M.D., F.A.C.P.**, Chief Medical Officer, Aptium Oncology Inc., Los Angeles, CA

**Discussant:** **Peter Enzinger, Ph.D.**, Clinical Director, GI Cancer Center, Dana Farber Cancer Institute; and Assistant Professor of Medicine, Harvard Medical School, Boston, MA

### **Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma**

**Presenter:** **Lisa Rimsza, M.D.**, Professor of Pathology, Arizona Cancer Center, University of Arizona Health Sciences Center; Chair, SWOG Lymphoma Translational Medicine Sub-Committee; and Vice Chair, SWOG Translational Medicine Committee, Tucson, AZ

**Discussant:** **Thomas Miller, M.D.**, Professor of Medicine, Chief, Section of Hematology/Oncology, Director, Lymphoma Program, Department of Medicine, Arizona Cancer Center, University of Arizona Health Sciences Center, SWOG, Vice Chair, Lymphoma committee, Tucson, AZ

### **Communicating the Early End of Intervention to Participants in a Large Ongoing Study**

**Presenter:** **Jo Ann Hartline, M.P.H.**, Project Manager, SELECT, SWOG Statistical Center, Seattle, WA

**Discussant:** **Gary Goodman, M.D.**, Staff Oncologist, Swedish Medical Center Cancer Institute; and Joint Member, Hutchinson Cancer Research Center, Seattle, WA

### **SWOG S0509: A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma**

**Presenter:** **Linda Garland, M.D.**, Associate Professor of Clinical Medicine, Director of Clinical Lung Cancer Program, Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, AZ

**Discussant:** **Harvey Pass, M.D.**, Professor of Cardiothoracic Surgery and Surgery Director, Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, New York University School of Medicine and Clinical Cancer Center, New York, NY